China Pharma Holdings (CPHI) Income from Continuing Operations (2010 - 2026)
China Pharma Holdings (CPHI) reported Income from Continuing Operations of 1143148.0 for Q1 2026, down 45.52% on a YoY basis from 2098209.0 in Q1 2025, and up 6.46% quarter-over-quarter from 1222135.0 in Q4 2025.
China Pharma Holdings (CPHI) Income from Continuing Operations (2010 - 2026) Analysis & Trends
China Pharma Holdings has reported Income from Continuing Operations for 17 years, with the latest figure at 1143148.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 45.52% year-over-year to 1143148.0; the trailing twelve-month figure through Mar 2026 stood at 3545132.0 (up 22.36% YoY), and the FY2025 full-year result was 3187556.0, up 32.7% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 1143148.0, up from 1222135.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 475976.0 in Q1 2023, with the low at 1438130.0 in Q2 2024.
- Historically, Income from Continuing Operations has averaged 948160.47 across 5 years, with a median of 955892.0 in 2024.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations plunged 142.51% — and 2025, when it jumped 63.26%.
- China Pharma Holdings' Income from Continuing Operations stood at 1264184.0 in 2022, then climbed by 2.53% to 1232213.0 in 2023, then increased by 0.63% to 1224432.0 in 2024, then grew by 0.19% to 1222135.0 in 2025, then gained by 6.46% to 1143148.0 in 2026.
- The last three Income from Continuing Operations figures came in at 1143148.0 (Q1 2026), 1222135.0 (Q4 2025), and 651482.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 370.00 Mn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 21.05 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 118.42 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | -92.12 Mn |
| 10 | China Pharma Holdings | 19.13 Mn | 18.97 Mn | 285,487.00 | -1.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.14 Mn |
| Dec 31, 2025 | -1.22 Mn |
| Sep 30, 2025 | -651,482.00 |
| Jun 30, 2025 | -528,367.00 |
| Mar 31, 2025 | -785,572.00 |
| Dec 31, 2024 | -1.22 Mn |
| Sep 30, 2024 | -1.12 Mn |
| Jun 30, 2024 | -1.44 Mn |
| Mar 31, 2024 | -955,892.00 |
| Dec 31, 2023 | -1.23 Mn |
| Sep 30, 2023 | -777,600.00 |
| Jun 30, 2023 | -593,029.00 |
| Mar 31, 2023 | -475,976.00 |
| Dec 31, 2022 | -1.26 Mn |
| Sep 30, 2022 | -790,773.00 |
| Jun 30, 2022 | -888,394.00 |
| Mar 31, 2022 | -1.03 Mn |
| Dec 31, 2021 | -980,719.00 |
| Sep 30, 2021 | -826,669.00 |
| Jun 30, 2021 | -824,761.00 |